Brought to you by:
SVS Foundation changes name of program aimed at providing care for underserved patients
The Society for Vascular Surgery (SVS) Foundation program formerly known as VISTA has a new name. VISTA—an acronym for Vascular Volunteers In Service To All—is now simply Vascular Care for the Underserved™. Its mission, however, remains the same: “to provide…
Vascular community starts process of wrestling with findings from BEST-CLI
One of the earliest multispecialty public gatherings of the vascular community following the release of the first results from the BEST-CLI randomized controlled trial (RCT) raised some of the early fault lines developing between different interpretations of the study’s key…
The 10 most popular Vascular Specialist stories of November 2022
Among November’s most read Vascular Specialist stories were updates from the BEST-CLI trial in the form of new data and funding; a guest editorial calling for (better) training vis-à-vis counseling patients about their treatment options; news of positive results from…
BEST-CLI: Optimal medical therapy adherence ‘well below’ recommended level at baseline
A significant proportion of patients enrolled in the BEST-CLI trial did not meet optimal medical therapy (OMT) guideline-based recommendations at the time of their entry into the study, co-principal investigator Matthew Menard, MD, told the 2022 New England Society for…
Miss the SVS webinars? Take advantage of the recordings
The Society for Vascular Surgery (SVS) hosts a number of Town Halls, roundtables and webinars for the benefit of its members. In the past few months, members were able to participate in a webinar on how best to use electronic…
SWING trial 12-month data: Novel sirolimus DCB shows ‘great promise’ in ‘challenging’ CLTI population
The Sundance (Surmodics) sirolimus drug-coated balloon (DCB) has an “excellent” safety profile in a “challenging, real-world, predominantly CLTI [chronic limb-threatening ischemia] population,” and has a primary patency rate of 80% at 12 months in a per-protocol analysis population. Ramon Varcoe,…
First data from BEST-CLI bring surgical bypass into the forefront of discussion for patients with high-quality great saphenous vein
The first results from the BEST-CLI randomized controlled trial (RCT) of 1,830 patients show that surgical bypass with adequate single-segment great saphenous vein (GSV) is a more effective revascularization strategy for patients with chronic limb-threatening ischemia (CLTI) who are deemed…
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66% at six months
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint target of 54%, chief investigator Daniel Clair, MD, told the 2022 Vascular Interventional Advances (VIVA) meeting…
BEST-CLI attracts $3.3m funding injection to continue data analysis
The Novo Nordisk Foundation has made a $3.3 million contribution toward the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb ischemia) clinical trial, the Denmark-based entity has announced. The grant is set to be used by investigators…
Roundtable for treating CLTI: GLASS will make it clear
The final of three roundtables on treating Chronic Limb-threatening Ischemia (CLTI) will cover the Global Limb Anatomic Staging System—GLASS. The virtual roundtable, on GLASS staging and treatment outcomes, will be held from 6 to 7:30 p.m. CDT Monday, Oct. 10.…